this post was submitted on 05 Sep 2024
830 points (98.0% liked)
Technology
59339 readers
5310 users here now
This is a most excellent place for technology news and articles.
Our Rules
- Follow the lemmy.world rules.
- Only tech related content.
- Be excellent to each another!
- Mod approved content bots can post up to 10 articles per day.
- Threads asking for personal tech support may be deleted.
- Politics threads may be removed.
- No memes allowed as posts, OK to post as comments.
- Only approved bots from the list below, to ask if your bot can be added please contact us.
- Check for duplicates before posting, duplicates may be removed
Approved Bots
founded 1 year ago
MODERATORS
you are viewing a single comment's thread
view the rest of the comments
view the rest of the comments
Ok, so we should be able to control the prices for drugs where the research has been publicly funded. But how do we avoid losing the private investors who contributed?
well, according to the congressional budget office,
and this report by research america shows that the private sector spent around $150 billion on “research and development” in 2019.
it’s no secret that the private healthcare industry jacks up the prices of things to increase profits. so, some napkin math makes me think it’s not that far-fetched to think that we can save more than $150 billion in healthcare subsidies if we stop privatized healthcare and dramatically lower the costs of medical care. we could then put that $150 billion back into research, without needing to appease the private sector at all.
Medicine still works in europe and is also being developed in europe. Maybe look at how the EU/european countries do it? A lot of it is having regulations. The free market isn't free if the choice between getting the product or not is the difference between life and death.
I am from EU, especially one of those countries with free health care. I believe we have a mix of public research, private research (ex: Sanofi, Servier), expensive proprietary drugs and government controlled public domain generic drugs. But there was an alert recently on drug making sovereignty because no company is interested in making those less profitable generic drugs in France, so they are outsourced to cheaper countries and there's a risk of penury.